Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Farxiga(Dapagliflozin Propanediol)AstraZeneca PLC logoAZN

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AstraZeneca PLC

$5.29B

Medicare cost, 2024

Medicare drug plans spent $5.3 billion on Farxiga (dapagliflozin propanediol) in 2024, for 5.6 million prescriptions and refills filled by 1.3 million patients. It ranks 8th among all drugs by Medicare drug plan spending. Spending rose 22% from 2023 to 2024. Texas accounts for the most spending ($470.4 million, 9% of the total).

Medicare cost, 2024

$5.29B

+21.8% from 2023

Prescriptions

5.6M

$938.93 per claim

Patients

1.3M

266,350 prescribers

Total spending, 2024

$5.29B

$4,168.36 per patient

Questions and answers

How much does Medicare spend on Farxiga?

Medicare prescription drug plans paid $5.29B for Farxiga in 2024, for 5,632,811 prescriptions and refills to 1,268,791 patients (up 21.8% from 2023). The average cost per claim was $938.93.

Which state spends the most on Farxiga?

Texas had the highest Medicare cost for Farxiga in 2024: $470.4M for 474,557 claims, followed by California ($450.5M).

Who prescribes Farxiga the most?

Wei Y Sun, nephrology in New York, NY, had the highest Medicare cost for Farxiga in 2024: 3,361 claims costing $2.2M.

Who makes Farxiga?

Farxiga is made by AstraZeneca PLC (AZN), listed in the Medicare spending data as Astrazeneca.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Farxiga was $5.29B in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Farxiga, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Wei Y Sun New York, NYNephrology3,361561$2.2M
Mohammad A Chaudhry Union City, NJInternal Medicine1,822436$1.9M
Carlos R Figueroa Nunez San Juan, PREndocrinology2,106401$1.4M
Francisco Pons Miami, FLInternal Medicine1,968457$1.3M
Ankush Gulati Lehigh Acres, FLNephrology1,028321$1.3M
Minesh Rajpal Peoria, AZNephrology1,068270$1.2M
Manavendra Bakhshi Philadelphia, PACardiology1,629309$1.2M
Luis R Garcia-Mayol Coral Gables, FLNephrology1,429303$1.2M
Paul-Moreau Bossous Mission, TXNephrology1,139374$1.2M
Nhan T Luu Galion, OHNephrology1,006285$1.2M
1710074026 Internal Medicine1,184235$1.2M
Najmuddin K Karimjee Houston, TXInternal Medicine1,073358$1.1M
Carlos M Martinez Rivera Mayaguez, PREndocrinology1,548310$1.1M
Eddie M Rodriguez-Castro Bayamon, PRNephrology903293$1.1M
Ahed Mansoura Rome, GAEndocrinology873225$1.1M
Michael M Dao Garden Grove, CAInternal Medicine1,002257$1.0M
Eliscer Guzman New York, NYInternal Medicine1,056297$1.0M
Henry C Yee Alhambra, CACardiology1,243292$1.0M
Elizabeth Liang Flushing, NYNephrology1,509263$996K
Glenn H Herrington Wilmington, NCPharmacist645216$985K
Jose R Baez Lawrence, MAInternal Medicine1,472248$948K
Denise Caro Mayaguez, PREndocrinology1,302234$941K
Stella Ilyayeva Rego Park, NYInternal Medicine1,165234$910K
Maritza Melendez Nieves Fajardo, PRInternal Medicine617185$900K
Lisa O Cabrera San Antonio, TXNephrology1,153271$896K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022178,6042,664,228638,606$2.58B
2023230,4774,296,969993,405$4.34B
2024266,3505,632,8111,268,791$5.29B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
AstrazenecaAZN logoAZN5,634,650$5.29B

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube